Tecartus First CAR T-Cell Therapy FDA Approved for Patients with Mantle-Cell Lymphoma

October/November 2020 Vol 13, No 5 - FDA Approvals
Download PDF

On July 24, 2020, the FDA accelerated the approval of brexucabtagene autoleucel (Tecartus; Kite Pharma), a CAR T-cell therapy, for the treatment of adults with mantle-cell lymphoma (MCL) whose disease has not responded to or has relapsed after other therapies. Brexucabtagene autoleucel is the first gene therapy FDA-approved specifically for the treatment of patients with MCL, a rare type of B-cell non-Hodgkin’s lymphoma.

The FDA granted brexucabtagene autoleucel a priority review, a breakthrough therapy designation, and an orphan drug designation.

Commenting on this FDA approval, Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research, said, “This approval is yet another example of customized treatments that use a patient’s own immune system to help fight cancer, while using a scientific advance in this promising new area of medicine. We’re seeing continued advances in the field of gene therapy and remain committed to supporting innovation in this promising new area of medicine.”

The FDA approved brexucabtagene autoleucel based on safety and efficacy results from a multicenter clinical trial of 60 adults with relapsed or refractory MCL who were followed for ≥6 months after their first objective response to treatment. The complete remission rate after treatment with brexucabtagene autoleucel was 62%, with an objective response rate of 87%.

Brexucabtagene autoleucel is created from the patient’s own immune system by collecting the patient’s cells and genetically modifying them to target the lymphoma cells. These modified T-cells are then infused back into the patient.

The most common (≥20%) adverse reactions occurring with brexucabtagene autoleucel include serious infections, low blood cell counts, and a weakened immune system. Side effects from treatment usually appear within the first 1 to 2 weeks after treatment, but some side effects may occur later.

Furthermore, brexucabtagene autoleucel is associated with a risk for cytokine release syndrome, a life-threatening condition, and neurologic toxicities. Because of these serious risks, brexucabtagene autoleucel is available only through a Risk Evaluation and Mitigation Strategy (REMS) program. This REMS program is identical to that of another CAR-T therapy (axicabtagene ciloleucel; Yescarta) from the same manufacturer.

To evaluate the long-term safety of brexucabtagene autoleucel, the FDA is requiring the manufacturer to conduct a postmarketing observational study of patients who received treatment with brexucabtagene autoleucel.

Related Items
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
Web Exclusives published on May 26, 2022 in FDA Approvals
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
Web Exclusives published on May 19, 2022 in FDA Approvals
Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker
Web Exclusives published on May 16, 2022 in FDA Approvals
Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma
Web Exclusives published on May 5, 2022 in FDA Approvals
Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma
Web Exclusives published on May 3, 2022 in FDA Approvals
Last modified: August 30, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.